CDG Invest Growth, via its Capmezzanine III fund, has successfully exited its investment in Soludia Maghreb, a Moroccan company recognized as a leading manufacturer of hemodialysis products. These products play a critical role in filtering waste and excess fluids from the blood for patients suffering from kidney failure. The stake was sold to Sothema, a prominent Moroccan pharmaceutical group.
Established in 1998, Soludia Maghreb has built a strong reputation in the healthcare sector. The company specializes in producing hemodialysis concentrates and distributing a wide range of pharmaceutical products and medical devices sourced from international laboratories. Its operations are central to supporting renal care and other therapeutic needs across Morocco and beyond.
Since its investment in December 2021, CDG Invest Growth has been instrumental in accelerating Soludia Maghreb’s growth trajectory. The partnership focused on several strategic initiatives, including:
- Modernizing the industrial platform to enhance production efficiency and quality standards.
- Diversifying into new therapeutic areas, expanding the company’s product portfolio beyond renal care.
- Strengthening the sales force to improve market penetration and customer engagement.
- Driving expansion through geographic growth and targeted acquisitions, positioning Soludia Maghreb as a regional leader.
Commenting on the transaction, Hassan Laaziri, CEO of CDG Invest Growth, stated:
This exit marks the culmination of a successful partnership with Soludia Maghreb, underpinned by operational improvements and accelerated growth. Transitioning ownership to Sothema, a leading industrial player, represents a significant milestone and opens new opportunities for industrial and commercial development.
